Previous 10 | Next 10 |
Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual Meeting 2021 -- Preclinical data presented at AACR highlight four precision therapies with first- or best-in-class potential -- -- IND application cleared by F...
Blueprint Medicines to Host Virtual Investor Event and Webcast to Review New Data Presented at AACR Annual Meeting on Monday, April 12, 2021 -- Presentations showcase the company's scientific leadership in precision oncology and hematology -- PR Newswire CAMBRIDGE,...
Halvorsen's 13F portfolio value increased from $27.68B to $36.37B. The number of positions increased from 86 to 96. Viking Global added UnitedHealth, AbCellera Biologics, Walt Disney, and Palo Alto Networks while dropping Analog Devices, CME Group, Comcast, and Exact Sciences. The...
CStone Pharmaceuticals (CSPHF) announced that the National Medical Products Administration (“NMPA”) of China has approved Gavreto (pralsetinib) for the treatment of a certain group of adult patients with non-small cell lung cancer (“NSCLC”).The once-daily...
Stephen Mandel’s 13F portfolio value increased ~19% from $23.20B to $27.51B. The number of positions increased from 32 to 41. Lone Pine Capital increased MercadoLibre and DexCom while dropping PayPal and Capital One Financial. The top three positions are Shopify, Coupa Soft...
With an estimated ~$530B war chest in total, large biopharma companies will continue to drive M&A activity in 2021, the analysts at Goldman Sachs predicted in a new analysis of the sector.Noting a ~110% YoY rise in deal volumes in February including ~221% YoY growth in U.S. mid-cap deals,...
Blueprint Medicines to Showcase Scientific Leadership in Precision Oncology and Hematology at AACR Annual Meeting 2021 -- Range of presentations highlight the company's research productivity and broad precision therapy portfolio -- PR Newswire CAMBRIDGE, Mass. , ...
Blueprint Medicines ([[BPMC]] -1.6%) has announced that the European Medicines Agency has validated its Type II variation marketing authorization application for Ayvakyt (avapritinib) for advanced systemic mastocytosis.With the decision, the company says that the submission process is suffici...
Blueprint Medicines Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT® (avapritinib) for the Treatment of Advanced Systemic Mastocytosis PR Newswire CAMBRIDGE, Mass. , March 3, 2021 /PRNewswire/ -- Blueprint Medici...
DCPH has seen some early success with ripretinib in 4th line and later GIST. However, the key to the mint is to show positive data in INTRIGUE, in 2nd line GIST for imatinib-refractory patients, and compared to sunitinib. That data will be out sometime in late 2021. For furt...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...
2024-07-10 04:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...